Both autoimmunity and tumor immunity are immune responses against self-tissues or cells. However, the precise similarity or difference between them remains unclear. In this study, to understand a novel mechanism of tumor immunity, we performed transplantation experiments with a murine autoimmune model, C57BL/6J (B6)/lpr mice. A melanoma cell line, B16F10 cells, or granulocyte macrophage colony-stimulating factor-overexpressing B16F10 (B16F10/ mGM) cells were transplanted into B6 or B6/lpr mice. Tumor growth by transplanted B16F10/mGM cells was significantly accelerated in B6/lpr mice compared with that in B6 mice. The accumulation of M1 macrophages in the tumor tissues of B6/lpr recipient mice was significantly lower compared with that in the control mice. In vitro co-culture experiment showed that impaired differentiation into M1 macrophages was observed in B6/lpr mice. The number of tumor vessels and vascular endothelial growth factor (VEGF) expression were also significantly enhanced in the tumor tissues of B6/lpr mice compared with those in the B6 mice. Moreover, VEGF expression was correlated with the increased expression of hypoxia-inducible factor-1α in the tumor tissues of B6/lpr mice. These results suggest that dysfunctional tumor immunity and enhanced angiogenesis in autoimmunity influence tumor growth.
Anti-tumor immune responses are operated during each step of tumor progression. 1, 2 However, in most cases, the anti-immune responses are suppressed and attenuated by tumors and tumor microenvironments, thus the immune responses are ineffective and insufficient. 1, 2 Various types of immune cells are associated with tumor immunity, including cytotoxic T cells, macrophages, dendritic cells, and regulatory T cells, which contribute to the survival, death, growth, and differentiation of the tumor cells via complex mechanisms. 3 In particular, a recent study showed that tumor-associated macrophages (TAMs) have key roles in the survival, invasion, motility, and intravasation of tumor cells. 4 Macrophages have highly diverse functions in different organs, local environments, and in response to antigens. 5, 6 It is well-known that there are two classes of macrophages: (i) activated (M1) macrophages that respond to tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and ligands/toll-like receptor 4: and (ii) alternately activated (M2) macrophages that respond to interleukin (IL)-4 and IL-13. 7 It has also been reported that TAMs are polarized into the two classes of tumor-killing (M1) and tumor-promoting (M2) macrophages. 8 The autoimmune response is known to be exceptionally complicated. 9, 10 Autoimmune diseases are caused by multiple factors, such as dysfunctional immune cells, dysregulation of the immune system, genetic factors, infections, and environmental factors. 9, 11, 12 Several studies have shown that macrophages have major roles in the onset or development of autoimmunity. 13, 14 In particular, activated M1 macrophages contribute to the enhancement or acceleration of experimental autoimmune encephalomyelitis and Sjögren's syndrome-like lesions in animal models. 15, 16 Therefore, during autoimmunity, we hypothesized that M1 macrophages may have an anti-tumor role in tumor immunity. In addition, recent studies of the relationship between autoimmunity and tumor immunity demonstrate that the incidence rate of some malignant tumors, such as hematological tumors, lung cancer, and thyroid cancer, is epidemiologically higher in the patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) than that in healthy controls. [17] [18] [19] [20] However, the precise relationship between autoimmunity and tumor immunity remains unclear.
In this study, to investigate a novel regulatory mechanism for tumor immunity mediated by macrophages, we performed transplantation experiments using a murine autoimmune model to analyze the development of tumors in an environment with autoimmunity.
MATERIALS AND METHODS
Mice and Tumor Transplantation C57BL/6J (B6) and B6-Fas lpr /J (B6/lpr) mice were purchased from the Japan SLC Laboratory (Shizuoka, Japan). Male mice were reared in our specific pathogen-free mouse colony, where food and water provided ad libitum. B16F1, B16F10, B16F10/mGM melanoma cells, and 3LL cells were supplied by RIKEN (No. RCB2649, RCB2630, and RCB1158) and National Institutes of Biomedical Innovation, Health and Nutrition (No. JCRB1348). The cells were maintained in DMEM (Wako Pure Chemical Industries, Ltd., Osaka, Japan) with 10% fetal bovine serum (FBS). Next, 10 6 cells in 100 μl PBS were injected subcutaneously into B6 or B6/lpr mice. At 3 weeks after injection, X-ray computed tomography (CT) images were captured using SkyScan 1176 system (Bruker microCT, Kontich, Belgium) and tumor volume was analyzed by CTAn (Bruker microCT), before analyzing the size and weight of tumors. In addition, the removed tumor tissues were used in further experiments. The survival ratio was calculated using the Kaplan-Meier method. This study was conducted in accordance with the 'Fundamental Guidelines for the Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions' under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government. The study protocols were approved by the Committee on Animal Experiments of Tokushima University (Permit Number: toku-15011).
Flow Cytometric Analysis
Infiltrating immune cells in tumor tissues were collected by enzymatic digestion using collagenase type I (Wako Pure Chemical Industries) and dispase (EIDIA, Tokyo, Japan). The suspended cells were analyzed using the following monoclonal antibodies (mAbs): FITC-, PE-, APC-, APC-Cy7-, PE-Cy7-, APC-eFluor780-, PerCP-Cy5.5, eFluor 450-, or Brilliant Violet 420-conjugated anti-mouse CD3, CD19, NK1.1, CD45.2, CD11b, CD11c, F4/80, and CD206 (eBioscience, San Diego, CA, USA). An EC800 analyzer (Sony Corporation, Tokyo, Japan) was employed to determine the cell populations, and the data were processed using EC800 v1.3.6 FACS analysis software (Sony Corporation). Cell numbers were determined with a Coulter particle counter (Beckman Coulter, Brea, CA, USA).
Histopathological and Immunofluorescence Analysis
Tumor tissues were removed from mice, fixed with 10% phosphate-buffered formaldehyde (pH 7.2) and prepared for histological examination. Sections were stained with hematoxylin and eosin. For the immunofluorescence analysis, paraffin-embedded sections were stained with anti-Ki-67 (Novus Biologicals, Littleton, CO, USA), anti-CD31 (Abcam, Cambridge, UK), anti-VEGF-A (Abcam), anti-pimonidazole (Hypoxyprobe, Burlington, MA, USA), and anti-HIF-1α (Novus Biologicals) mAb, before applying an Alexa-555-conjugated secondary antibody. The nuclei were stained with 4',6-diamidino-2-phenylindole (Life Technologies, Carlsbad, CA, USA). A Hypoxyprobe-1 Omni kit (Hypoxyprobe) was used to detect hypoxia in tumor cells. Briefly, 1.5 mg pimonidazol was injected intraperioneally into mice transplanted with tumors. The tumor tissues were fixed at 30 min after injecting pimonidazol and then the hypoxic cells were then detected by immunofluorescence analysis. The images were acquired using an Observer Z1 (Carl Zeiss, Oberkochen, Germany) and analyzed with AxioVision SE64 (Carl Zeiss).
ELISA
The concentration of vascular endothelial growth factor (VEGF) in tumor tissues was measured using a mouse VEGF ELISA kit (RayBiotech, Norcross, GE, USA). Diluted samples or standard recombinant VEGF were added to 96-well flat-bottomed plates precoated with capture antibodies. After washing the plates, biotinylated antibodies were added and the wells were incubated with streptavidin conjugated horseradish peroxidase (HRP). Tetramethylbenzidine solution was added to each well as the substrate. The optimal density at 450 nm was measured using a microplate reader (model 680; Bio-Rad Laboratories, Hercules, CA, USA).
Real-Time RT-PCR Total RNA was isolated from removed tumor tissues using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). Total RNA was reverse transcribed using a PrimeScript RT reagent kit (Takara Bio, Shiga, Japan) and the obtained cDNA was used as the PCR template. Transcript levels were determined using a 7300 Real-time PCR System (Life Technologies) with SYBR Premix Ex Taq (Takara Bio). The primer sequences used are shown in Supplementary Table S1. The relative mRNA expression level of each transcript was normalized against that of β-actin or F4/80 mRNA. 
Western Blot Analysis
Tissues were homogenized and lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 0.1% Triton X-100, and 1 mM EDTA) supplemented with protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). Protein concentration in Bio-Rad protein assay dye reagent concentrate (Bio-Rad Laboratories) was determined by measuring the absorption at 595 nm on a microplate reader (Bio-Rad Laboratories). A total of 20 μg of each sample per well was subjected to 10% SDS-PAGE gel and blotted onto nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK). After blocking with 3% nonfat skim milk, the membranes were incubated with anti-HIF-1α mAb overnight at 4°C, followed by washing and the addition of a HRP-conjugated secondary antibody for 1 h. Protein bands were visualized using an Immobilon Western Chemiluminescent HRP Substrate (Merck KGaA, Darmstadt, Germany). Densitometric analysis was performed to determine the ratio of HIF-1α relative to β-actin.
Statistical Analysis
The results are presented as means ± s.d. Comparisons of the results obtained for two groups were performed using an unpaired, two-tailed Student's t-test. Po0.05 was considered significant.
RESULTS

Transplantation of Melanoma into B6/lpr Mice
We used B16F10 melanoma cells that are more metastatic and aggressively proliferative than the parental cell line B16F1. 21 B16F10 melanoma cells were injected subcutaneously into C57BL/6 (B6) and B6/lpr mice. The recipient mice were analyzed 3 weeks after the injection. The findings of the CT analysis indicated that there was no difference in the size of the transplanted tumors between B6 and B6/lpr recipients ( Figure 1a ). In addition, there was no significant difference in the weight of tumor masses in the B6 and B6/lpr recipient mice ( Figure 1b Figure S1c and S1d). Although these results indicate that the autoimmunity had no effect on the growth of aggressively proliferative B16F10 melanoma cells, there might be any deficiency of differentiation or migration of M1 phenotype TAMs.
Therefore, we next focused on TAMs. In order to activate M1 macrophages in vivo, granulocyte macrophage colony-stimulating factor (GM-CSF)-overexpressing B16F10 (B16F10/mGM) cells were transplanted subcutaneously into B6 and B6/lpr mice. It has been reported that the syngeneic transplantation of B16F10/mGM cells leads to the suppression of tumor growth and lung metastasis. 22 Interestingly, the volume and weight of the tumors in B6/lpr recipient mice were significantly higher compared with those in the control recipients (Figure 1c and d) . In addition, the survival rate of the B6/lpr recipient mice decreased to 60% at 3 weeks after tumor injection, whereas all of the B6 recipient mice were alive ( Figure 1e ).
Histopathological analysis showed that the focus of necrosis in transplanted B16F10/mGM cells was markedly observed in B6/lpr recipients ( Figure 2a , upper panel). Moreover increased abnormal mitosis was also observed in B6/lpr recipients ( Figure 2a , lower panel). The number of tumor cells that exhibited abnormal mitosis in B6/lpr recipient mice was significantly higher compared with that in B6 mice ( Figure 2b ). In addition, the number of Ki-67 + -proliferating tumor cells in B6/lpr mice was significantly higher than that in B6 mice (Figure 2c and d). These findings suggest that tumor development may be enhanced in an autoimmunity model through the change of tumor environment.
Macrophages in Transplanted Tumor
The immune cell populations in transplanted B16F10/mGM tumor tissues were analyzed by flow cytometry (Supplementary Figure S2a) . There was no difference in the proportion of CD11b + F4/80 + TAMs and CD11b + F4-/80 + CD11c + CD206 − M1 (anti-tumor) TAMs in between B6 and B6/lpr mice (Figure 3a-d) . By contrast, the proportion of CD11b + F4/80 + CD11c − CD206 + M2 TAMs in B6/lpr recipient mice was significantly higher compared with that in control recipient mice (Figure 3b and e). The number of CD11b + F4-/80 + TAMs in B6/lpr recipient mice was significantly lower compared with that in control recipient mice (Figure 3f ). In addition, the number of CD11b + F4/80 + CD11c + CD206 − M1 (anti-tumor) TAMs in B6/lpr recipient mice was significantly lower compared with that in B6 control recipient mice (Figure 3g ). Although there was no difference in the number of CD11b + F4/80 + CD11c − CD206 + M2 TAMs in B6 and B6/lpr mice (Figure 3h ), the total number of M2 TAMs in whole tumor mass, not the cell number/g, in B6/lpr recipients was significantly higher compared with that in B6 recipients (Supplementary Figure S2b) . In addition, the M1/M2 ratio of TAMs in B6/lpr recipient mice was reduced significantly compared with that in B6 mice (Figure 3i ). However, there were no differences in the numbers of CD3 + T cells, CD19 + B cells, and NK1.1 + CD3 − NK cells in the tumor tissues of B6 and B6/lpr recipient mice (Supplementary Figure S2c) . Also, Cross-talk between autoimmunity and tumor immunity T Kondo et al Figure  S3) . IFN-γ mRNA expression of spleen in B6/lpr was significantly increased compared with that in B6 mice (Supplementary Figure S3) . In addition, it was reported that IFN-γ level of sera in B6/lpr mice was significantly higher than that in control mice. 23 Therefore, the environment in tumor tissue may be different from the peripheral condition in this model. To understand the differentiation of peripheral macrophages into M1 macrophages in B6/lpr mice in the presence of GM-CSF, the spleen cells from B6 and B6/lpr mice were co-cultured with B16F10 or B16F10/mGM cells using a chamber system. After co-culture with B16F10/mGM cells, 
CD206
+ M2 macrophages in B6/lpr mice co-cultured with B16F10 cells increased significantly compared with that in B6 mice (Figure 4e ). There was no difference in the M2 macrophages co-cultured with B16F10/mGM cells in B6 and B6/lpr mice (Figure 4e) . Furthermore, the M1/M2 ratio of spleen cells in B6/lpr mice co-cultured with B16F10/mGM cells was significantly lower than that in B6 mice (Figure 4f ). 
Cross-talk between autoimmunity and tumor immunity T Kondo et al
These findings suggest that an imbalance in differentiation into M1/M2 macrophages is associated with in vivo tumor growth in B6/lpr recipients. In addition, we analyzed the mRNA expression of GM-CSF receptor Csf2ra of the transplanted tumor tissues in B6 and B6/lpr recipients. There was no difference in the mRNA expression level of Csf2ra in the tumor tissues between B6 and B6/lpr recipients (Supplementary Figure S5a) . Moreover, spleen cells from B6 and B6/lpr mice were cultured in the presence of GM-CSF for 48 h to promote differentiation into M1 macrophage. Although the proportion of F4/80 + CD11b + cells in response to GM-CSF (10 and 50 ng/ml) in B6/lpr mice was significantly lower than that in B6 mice (Supplementary Figure S5b) , there was no difference in the proportion of CD11c + CD206 − F4/80 + CD11b + M1 macrophage and a M1/M2 ratio between B6 and B6/lpr mice (Supplementary Figure S5c-e) . These findings suggest that the impaired function and accumulation of M1 TAMs in B6/lpr mice is not only by GM-CSF but also by the other factor in the environment of autoimmunity.
Tumor Angiogenesis in B6/lpr Recipient Mice
Regarding to enhanced tumor growth in B6/lpr recipients, several effects by TAMs were considered, which are a dysfunction of cytotoxic activity by TAMs, an enhanced effect on proliferation of tumor cells by TAMs, and promoted angiogenesis by TAMs. Thus, we investigated the in vitro cytotoxicity of spleen cells against B16F10/mGM cells. We found that there was no difference in the tumor cytotoxicity of spleen cells in both B6 and B6/lpr mice (Supplementary Figure S6a) , thereby indicating that there was no effect of the autoimmune response in B6/lpr mice on the direct cytotoxic activity against tumor cells. In addition, there was no effect of spleen cells including macrophages on the proliferation of B16F10/mGM cells by in vitro co-culture assay (Supplementary Figure S6b) . Therefore, we focused on the effect of TAMs on angiogenesis in B6/lpr mice. To elucidate tumor angiogenesis, immunofluorescence analysis was performed to detect CD31 + endothelial cells. There were increases in CD31 + endothelial cells in B6/lpr recipient mice compared with the control recipient mice (Figure 5a ). The number of vessels in the tumor tissue of B6/lpr recipient mice was significantly higher compared with that in the control recipient mice (Figure 5b ). In addition, VEGF, one of the key factors for angiogenesis, was quantified by ELISA in the tumor tissues. A significantly higher level of VEGF protein was detected in the tumor tissue from B6/lpr recipient mice compared with that from the control recipient mice (Figure 5c ). Moreover, the VEGF mRNA expression level in the tumor tissue from B6/lpr recipient mice was significantly higher than that from the control recipient mice (Figure 5d ). There was a correlation between the VEGF mRNA expression level and tumor weight in both B6 and B6/lpr recipient mice (Figure 5e ), but the correlation between VEGF mRNA expression and tumor weight was considerably stronger in B6/lpr recipient mice than that in B6 recipient mice (Figure 5e ). Furthermore, we performed additional experiments with transplantation of less aggressive tumor cells, B16F1 cells, and mouse lung cancer cell line, 3LL cells. Significantly increased weight of transplanted B16F1 and 3LL tumor mass of B6/lpr recipient mice were observed compared with that of control recipient mice (Supplementary Figure S7a  and d) . In addition, the number of CD31 + vessels in the 3LL and B16F1 tumor tissue of B6/lpr recipient mice was significantly higher compared with that in the control recipient mice (Supplementary Figure S7b, c and e) . By contrast, there was no difference in the number of vessels in transplanted B16F10 at 3 weeks after tumor injection between B6 and B6/lpr recipients (Supplementary Figure S8) . These results suggest that enhanced angiogenesis contributes to accelerated tumor growth in B6/lpr recipient mice.
Molecular Mechanism of Increased VEGF Expression in B6/lpr Recipient Mice
To examine whether tumor cells can produce VEGF by the interaction with immune cells including macrophages, B16F10/mGM cells were co-cultured with spleen cells of B6 and B6/lpr mice, and then VEGF mRNA expression of the tumor cells was measured by real-time RT-PCR. VEGF mRNA expression of B16F10/mGM cells co-cultured with spleen cells of B6/lpr mice was significantly enhanced compared with that of B6 mice (Figure 6a ). In addition, when determining the distribution of VEGF expression by immunofluorescence analysis, it was found that the expression of tumor tissue in the control recipient mice was localized to the tumor stromal tissue (Figure 6b ). By contrast, VEGF in the tumor tissue of B6/lpr recipient mice was expressed in both tumor cells and stromal tissue (Figure 6b ). On the other hand, we analyzed VEGF mRNA expression of B16F10/mGM and B16F10 cells. VEGF mRNA expression of B16F10/mGM cells was significantly lower than that of B16F10 cells (Supplementary Figure S9) , suggesting that GM-CSF may regulate the expression of VEGF from tumor cells. As shown in Figure 2a , considerable tumor necrosis was observed in the tumor tissue from B6/lpr recipient mice. Therefore, we considered that hypoxia as well as accelerated tumor growth might be induced in the tumor tissue of B6/lpr recipient mice. To detect hypoxia in tumor cells, pimonidazol was injected intraperitoneally as a hypoxia marker molecule into mice transplanted with tumors. At 30 min after of pimonidazol injection, the tumor tissues were fixed and hypoxic cells were detected by immunofluorescence analysis using anti-pimonidazol polyclonal antibody. Focal hypoxic cells were observed in the tumor tissues of B6 recipient mice (Figure 6c) , whereas hypoxic cells were widespread and observed diffusely in the tumor tissues from B6/lpr recipient mice (Figure 6c ). Hypoxic area (%) in the tumor tissues from B6/lpr recipient mice was significantly larger than that from B6 recipient mice (Figure 6d ). In addition, it is well known that hypoxia-inducible factor-1α (HIF-1α) activates the transcription of VEGF in tumor cells 24 and higher expression level of HIF-1α was found in the tumor tissues of B6/lpr recipient mice compared with the control recipient mice (Figure 6e) . The increased expression level of HIF-1α in the transplanted tumor tissues of B6/lpr recipients was also confirmed by western blotting (Figure 6f and g ). These results suggest that the enhancement of angiogenesis via the upregulation of VEGF by HIF-1α help to promote tumor growth in an animal model of autoimmunity.
Enhanced Angiogenesis in B16F1 Tumor Tissues in B6/lpr Recipients To further understand the mechanism of enhanced angiogenesis in B6/lpr recipients, when we analyzed the number of vessels in the early stage (10 days after injection of B16F10/mGM cells) in which there was no difference in tumor size between B6 and B6/lpr mice (Figure 7a ), the number of vessels, hypoxic area, and HIF-1α expression in the tumor tissue of B6/lpr recipient mice were significantly higher compared with those in the control recipient mice (Figure 7b-d, Supplementary Figure S10a-c) . In addition, VEGF expression in the tumor tissue of B6/lpr recipient mice was significantly higher compared with that in the control recipient mice (Figure 7e, Supplementary Figure S10d) . Therefore, enhanced angiogenesis in B6/lpr recipients was not caused by different size of transplanted tumors.
DISCUSSION
Previously, it was reported that there is a clear increased risk of malignant lymphoma and cancers of the vulva, the lung, and the thyroid gland in patients with autoimmune diseases. [17] [18] [19] [20] In addition, a meta-analysis demonstrated an increased risk of malignant lymphoma and lung cancer in patients with RA. 25 There are several possible explanations for the link between lymphoma and autoimmune diseases. 26, 27 It is known that translocations involving the juxtaposition of an oncogene adjacent a gene that is important for immune cell function may be associated with the onset of lymphoma. 28, 29 The alterations caused by translocation are proportional to the rate of lymphocyte proliferation, which may explain the increased risk of lymphoma in autoimmune diseases. It has also been reported that mucosa-associated lymphoid tissue lymphoma is the most common lymphoma in primary Sjögren's syndrome. 30 However, the precise mechanism that underlies this association remains unclear, and thus it is difficult to understand the relationship between tumors other than lymphoma and autoimmunity. In this study, we analyzed TAMs in B6/lpr mice in a transplantation experiment with GM-CSF-overexpressing melanoma cell line. Cross-talk between autoimmunity and tumor immunity T Kondo et al We also investigated the molecular mechanism of tumor growth in B6/lpr mice. A lot of reports demonstrate that immunological tolerance contributes controlling tumor immunity. 31, 32 However, in some reports, both merit and demerit effects on anti-tumor immunity were described. 32, 33 Our results demonstrate that the environment in autoimmunity contributes to the growth of transplanted tumor through disorder of M1 TAM accumulation or enhanced angiogenesis.
On the other hand, as the effect of autoimmune response on anti-tumor immunity in spontaneously occurring models is unclear, further study would be helpful for understanding the complicated tumor immunity system. Macrophages have a key role in the link between inflammation and carcinogenesis, 4, 34, 35 and many studies have demonstrated that TAMs promote tumor progression. 8, 36 For example, the overexpression of CCL2 by murine fibroblast cells leads to increased TAM infiltration, which promotes tumor growth in a mouse model. 37 In addition, macrophages play a crucial role in regulating tumor growth, survival, metastasis of tumor cells, angiogenesis, and immunosuppression. 34, 35 Several studies have found that TAMs exhibit an IL-12 low/IL-10 high phenotype with upregulated VEGF, EGF, COX2, and MMPs, which promote tumor growth. [38] [39] [40] In the present study, GM-CSF-overexpressing melanoma cells were transplanted into B6/lpr mice to promote the accumulation of monocytes or macrophages in the tumor tissues. The lower number of M1 TAMs in B6/lpr mice demonstrated the insufficient anti-tumor function of TAMs whereas there were no differences in the numbers of infiltrating T, B, and NK cells in the tumor tissues of B6/lpr mice. These findings suggest that the tumor immune system is impaired in the condition of autoimmunity. It is possible that the insufficient accumulation of TAMs in B6/lpr mice may disrupt the network of tumor immunity as well as decreasing the control of tumor growth. However, the precise cellular or molecular mechanisms that underlie the disruption of tumor immunity remain unclear.
GM-CSF is one of the key factors involved in the activation of macrophages or dendritic cells. 22 In particular, GM-CSF derived from tumor cells stimulates the secretion of macrophage metalloelastase and the production of angiostatin by tumor-infiltrating macrophages, which are associated with tumor growth and metastasis. 41 In this study, there was no significant difference in B6 and B6/lpr recipient mice transplanted with B16F10 cells, although the tumor weight was significantly higher in B6/lpr mice transplanted with B16F10/mGM cells. As described in previous studies, 22 tumor growth of B16F10/mGM cells was significantly lower in both B6 and B6/lpr mice compared with that of B16F10 in this study. The findings suggest that GM-CSF produced from B16F10/mGM cells attract and activate macrophages in the tumor environment. Moreover, we confirmed the enhanced growth of less progressive B16F1 and 3LL cells in B6/lpr recipients similar to B16F10/mGM cells. As shown in Figure 1 , the tumor weight of B16F10 cells in both B6 and B6/lpr recipients was roughly twice as large as that of B16F10/mGM cells. Anti-tumor effect of GM-CSF in B16F10/mGM cells has been reported. 22 Therefore, the discrepancy in the cell number of M2 TAMs between transplanted B16F10 and B16F10/mGM cells might be caused by the difference of tumor growth. Moreover, it was reported that target deletion of Fas in CD11b + myeloid cells could greatly enhance the number of activated proinflammatory macrophages. 42 However, it is still unclear why the macrophages from B6/lpr are resistant to attraction and activation by GM-CSF in the tumor environment. Cross-talk between autoimmunity and tumor immunity T Kondo et al
